Jubilant Life Sciences got ANDA nod for hypertension tablets
The Dollar Business Bureau
Jubilant Life Sciences, global pharma and life sciences major, has announced on Wednesday that it has got the final ANDA (Abbreviated New Drug Application) approval for generic drugs, used in the treatment for hypertension.
“Jubilant Life Sciences has got final ANDA (Abbreviated New Drug Application) approval for Felodipine Extended-Release Tablets USP, 2.5 mg, 5 mg, and 10 mg, the generic version of Plendil Tablets of AstraZeneca, which is used for the treatment of hypertension,’ the company said in a statement.
As of June 30 this year, the global pharmaceutical and life sciences company had an overall of 770 filings for Oral Solids, out of which 578 filings have been approved in several regions around the world. This consists of 70 ANDAs filed in the United States, out of which it got approval for 44 filings. The company has filed 104 ANDA applications in Europe.
On August 24, the company said that it had got final ANDA approval for Telmisartan tablets USP 80, 40 and 20mg, a generic version of Micardis tablets of Boehringer Ingelheim Pharma company, used in hypertension treatment.
Jubilant Life Sciences Ltd is an integrated global pharma and life sciences firm engaged in manufacturing and supplying of APIs, Radiopharmaceuticals, Solid Dosage Formulations, Life Science Ingredients and Allergy Therapy Products. The company has 11 world-class manufacturing units in India, US and Canada, withcustomers spread in more than 100 countries.